The aim of this work is to evaluate the performances of a commercial software, which “perturbs” the calculated dose distribution according to the dose discrepancies detected with planar or volumetric measurements in order to predict the actually delivered 3D dose distribution in the patient. The software was then used to evaluate the perturbed DVH for a sample of patients and to investigate the correlation between the gamma passing rate and the DVH modifications.
AOUC experience on patient-based dose verification: from gamma passing-rate to DVH / L. Marrazzo; M. Casati; C. Arilli; A. Compagnucci; S. Pallotta; C. Talamonti; E. Vanzi; M. Bucciolini. - (2013), pp. 30-30. (Intervento presentato al convegno 8° Congresso Nazionale AIFM tenutosi a Torino nel 2013).
AOUC experience on patient-based dose verification: from gamma passing-rate to DVH.
L. Marrazzo;PALLOTTA, STEFANIA;TALAMONTI, CINZIA;VANZI, ELEONORA;BUCCIOLINI, MARTA
2013
Abstract
The aim of this work is to evaluate the performances of a commercial software, which “perturbs” the calculated dose distribution according to the dose discrepancies detected with planar or volumetric measurements in order to predict the actually delivered 3D dose distribution in the patient. The software was then used to evaluate the perturbed DVH for a sample of patients and to investigate the correlation between the gamma passing rate and the DVH modifications.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
